News

Talazoparib Plus Avelumab Demonstrates Clinical Benefit for Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer

10/27/2022

Derek Cowsert

Talazoparib and avelumab demonstrated a favorable toxic effect profile and clinical benefit for patients with recurrent mismatch repair proficient endometrial cancer, according to findings from a clinical trial.

Talazoparib and avelumab...

10/27/2022

Oncology

Conference Coverage

Triplet Therapy Improves Response, Demonstrates Acceptable Safety in Recurrent Endometrial Cancer

06/21/2022

Janelle Bradley

Treatment with rucaparib, bevacizumab, and atezolizumab is feasible, demonstrating clinically meaningful improvement in response with acceptable safety for patients with recurrent endometrial cancer, according to a phase 2 trial.

Treatment with rucaparib,...

06/21/2022

Oncology

Conference Coverage

Camrelizumab Plus Apatinib Demonstrates Promising Antitumor Activity, Manageable Safety in Endometrial Cancer

06/09/2022

Janelle Bradley

In a phase 2 trial, camrelizumab plus apatinib demonstrated promising antitumor activity and manageable safety in patients with advanced or recurrent endometrial cancer that did not respond to first-line therapy.

In a phase 2 trial, camrelizumab...

06/09/2022

Oncology

News

Upfront MGPT Improves Lynch Syndrome Diagnosis in Patients With Endometrial Cancer

05/29/2021

According to data being presented at ASCO 2021, the use of upfront MGPT in patients with endometrial cancer has improved the detection of Lynch syndrome among this population.

According to data being...

05/29/2021

Oncology

News

Experts Discourage Intensive Follow-Up of Patients Treated for Endometrial Cancer

05/25/2021

According to study findings presented at the 2021 ASCO Annual Meeting, the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer should be discouraged.

According to study findings...

05/25/2021

Oncology

News

Endometrial Cancer Incidence Tied to Obesity in Young Adult Women

05/25/2021

At the 2021 ASCO Annual Meeting, researchers presented data from a study evaluating trends in endometrial cancer incidence and its relationship to obesity in the United States.

At the 2021 ASCO Annual Meeting,...

05/25/2021

Oncology

News

FDA Approves Dostarlimab-gxly for Adults With dMMR Endometrial Cancer

04/22/2021

Hina M. Porcelli

The FDA has approved dostarlimab-gxly for the treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed during or after a platinum-containing therapy.

The FDA has approved...

04/22/2021

Oncology

Conference Insider

No Survival Benefit With Adjuvant Chemo or RT for Endometrial Cancer

03/30/2021

Post-operative systemic chemo and RT did not improve OS in high-risk patients with stage I endometrial cancer, according to Rachelle Findley, MD, et al.

Post-operative systemic chemo...

03/30/2021

Oncology

News

Using Postmenopausal Bleeding to Detect Endometrial Cancer

09/19/2020

Evaluating women for postmenopausal bleeding aids in the early detection of, and implementation of prevention strategies for, endometrial cancer.

Evaluating women for...

09/19/2020

Oncology

News

Long-Term Cardiovascular Adverse Events Among Survivors of Endometrial Cancer

05/08/2020

Survivors of uterine cancer are at higher risk of experiencing cardiovascular problems years after treatment.

Survivors of uterine cancer are...

05/08/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology